Literature DB >> 34085137

Norepinephrine and dobutamine improve cardiac index equally by supporting opposite sides of the heart in an experimental model of chronic pulmonary hypertension.

Janus Adler Hyldebrandt1, Nikolaj Bøgh2, Camilla Omann3, Peter Agger4.   

Abstract

BACKGROUND: Pulmonary hypertension is a significant risk factor in patients undergoing surgery. The combined effects of general anaesthesia and positive pressure ventilation can aggravate this condition and cause increased pulmonary blood pressures, reduced systemic blood pressures and ventricular contractility. Although perioperative use of inotropic support or vasopressors is almost mandatory for these patients, preference is disputed. In this study, we investigated the effects of norepinephrine and dobutamine and their ability to improve the arterio-ventricular relationship and haemodynamics in pigs suffering from chronic pulmonary hypertension.
METHOD: Pulmonary hypertension was induced in five pigs by banding the pulmonary artery at 2-3 weeks of age. Six pigs served as controls. After 16 weeks of pulmonary artery banding, the animals were re-examined under general anaesthesia using biventricular conductance catheters and a pulmonary artery catheter. After baseline measurements, the animals were exposed to both norepinephrine and dobutamine infusions in incremental doses, with a stabilising period in between the infusions. The hypothesis of differences between norepinephrine and dobutamine with incremental doses was tested using repeated two-way ANOVA and Bonferroni multiple comparisons post-test.
RESULTS: At baseline, pulmonary artery-banded animals had increased right ventricular pressure (+ 39%, p = 0.04), lower cardiac index (- 23% p = 0.04), lower systolic blood pressure (- 13%, p = 0.02) and reduced left ventricular end-diastolic volume (- 33%, p = 0.02). When incremental doses of norepinephrine and dobutamine were administered, the right ventricular arterio-ventricular coupling was improved only by dobutamine (p < 0.05). Norepinephrine increased both left ventricular end-diastolic volume and left ventricular contractility to a greater extent (p < 0.05) in pulmonary artery-banded animals. While the cardiac index was improved equally by norepinephrine and dobutamine treatments in pulmonary artery-banded animals, norepinephrine had a significantly greater effect on mean arterial pressure (p < 0.05) and diastolic arterial pressure (p < 0.05).
CONCLUSION: While norepinephrine and dobutamine improved cardiac index equally, it was obtained in different manners. Dobutamine significantly improved the right ventricular function and the arterio-ventricular coupling. Norepinephrine increased systemic resistance, thereby improving arterial pressures and left ventricular systolic function by maintaining left ventricular end-diastolic volume.

Entities:  

Keywords:  Animal model; Dobutamine; Experimental model; Inotropes; Norepinephrine; Pulmonary hypertension; Vasopressor; Ventricular dysfunction

Year:  2021        PMID: 34085137     DOI: 10.1186/s40635-021-00391-x

Source DB:  PubMed          Journal:  Intensive Care Med Exp        ISSN: 2197-425X


  25 in total

Review 1.  Perioperative risk and management in patients with pulmonary hypertension.

Authors:  Omar A Minai; Jean-Pierre Yared; Roop Kaw; Kathirvel Subramaniam; Nicholas S Hill
Journal:  Chest       Date:  2013-07       Impact factor: 9.410

2.  Noncardiothoracic nonobstetric surgery in mild-to-moderate pulmonary hypertension.

Authors:  L C Price; D Montani; X Jaïs; J R Dick; G Simonneau; O Sitbon; F J Mercier; M Humbert
Journal:  Eur Respir J       Date:  2009-11-06       Impact factor: 16.671

3.  Acute right ventricular dilatation in response to ischemia significantly impairs left ventricular systolic performance.

Authors:  C Brookes; H Ravn; P White; U Moeldrup; P Oldershaw; A Redington
Journal:  Circulation       Date:  1999-08-17       Impact factor: 29.690

4.  Pulmonary hypertension: an important predictor of outcomes in patients undergoing non-cardiac surgery.

Authors:  Roop Kaw; Vinay Pasupuleti; Abhishek Deshpande; Tarek Hamieh; Esteban Walker; Omar A Minai
Journal:  Respir Med       Date:  2010-12-31       Impact factor: 3.415

5.  Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada.

Authors:  D Thiwanka Wijeratne; Katherine Lajkosz; Susan B Brogly; M Diane Lougheed; Li Jiang; Ahmad Housin; David Barber; Ana Johnson; Katharine M Doliszny; Stephen L Archer
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2018-02

6.  Perioperative mortality in patients with pulmonary hypertension undergoing major joint replacement.

Authors:  Stavros G Memtsoudis; Yan Ma; Ya Lin Chiu; J Matthias Walz; Robert Voswinckel; Madhu Mazumdar
Journal:  Anesth Analg       Date:  2010-09-14       Impact factor: 5.108

7.  Impact of pulmonary hypertension on the outcomes of noncardiac surgery: predictors of perioperative morbidity and mortality.

Authors:  Gautam Ramakrishna; Juraj Sprung; Barugur S Ravi; Krishnaswamy Chandrasekaran; Michael D McGoon
Journal:  J Am Coll Cardiol       Date:  2005-05-17       Impact factor: 24.094

8.  Effects of milrinone and epinephrine or dopamine on biventricular function and hemodynamics in an animal model with right ventricular failure after pulmonary artery banding.

Authors:  Janus Adler Hyldebrandt; Eleonora Sivén; Peter Agger; Christian Alcaraz Frederiksen; Johan Heiberg; Kristian Borup Wemmelund; Hanne Berg Ravn
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-05-08       Impact factor: 4.733

9.  Severe pulmonary hypertension complicates postoperative outcome of non-cardiac surgery.

Authors:  H-C Lai; H-C Lai; K-Y Wang; W-L Lee; C-T Ting; T-J Liu
Journal:  Br J Anaesth       Date:  2007-06-18       Impact factor: 9.166

Review 10.  Echocardiographic evaluation of diastolic function in the setting of pulmonary hypertension.

Authors:  Vineet Agrawal; Benjamin F Byrd; Evan L Brittain
Journal:  Pulm Circ       Date:  2019-02-05       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.